Table 3.
Obese pre-diabetic patient treated by a hypocaloric diet added to the placebo (group 2) at baseline vs. 12 months of follow-up.
| Study variables | Group 2 (n 20) at baseline | Group 2 (n 20) at 12 months of follow-up | P-value |
|---|---|---|---|
| CLINICAL VARIABLES | |||
| BMI (Kg/m2) | 33.5 ± 2.6 | 32.3 ± 0.9 | / |
| Systolic arterial pressure (mmHg) | 129 ± 12 | 125 ± 11 | / |
| Diastolicarterial pressure (mmHg) | 72 ± 10 | 77 ± 2.2 | / |
| Heart rate (beats for minute) | 84 ± 2.1 | 71 ± 5 | / |
| WHR | 0.91 ± 0.005 | 0.88 ± 0.005 | / |
| HOMA-IR | 4.9 ± 0.68 | 5.0 ± 0.68 | / |
| Insulin(μU/ml) | 20.1 ± 1.8 | 20.1 ± 1.5 | / |
| Glucose (mmol/L) | 6.73 ± 0.24 | 6.68 ± 0.2 | / |
| Cholesterol(mmol/L) | 4.51 ± 0.88 | 4.15 ± 0.94 | <0.05‡ |
| HDL(mmol/L) | 1.83 ± 0.39 | 1.84 ± 0.4 | / |
| LDL(mmol/L) | 3.33 ± 0.57 | 3.19 ± 0.57 | / |
| Triglycerides(mmol/L) | 1.83 ± 0.54 | 1.71 ± 1.18 | <0.05‡ |
| Creatinine (mmol/L) | 101.2 ± 3.5 | 99.4 ± 3.5 | / |
| BIOHUMORAL MARKERS | |||
| CRP (mmol/L) | 1.03 ± 0.43 | 0.57 ± 0.03 | / |
| IL6(pg/ml) | 4.10 ± 0.39 | 4.05 ± 0.27 | / |
| TNFα (pg/ml) | 6.75 ± 0.53 | 6.55 ± 0.53 | / |
| Nitrotyrosine (nmol/l) | 5, 092 ± 0, 651 | 4, 511 ± 0, 251 | / |
| ECHOCARDIOGRAPHICPARAMETERS | |||
| Intima-media tickness (mm) | 1.03 ± 0.18 | 1.01 ± 0.16 | / |
| LVTDd (mm) | 55 ± 4.1 | 55 ± 2.1 | / |
| LVTSd (mm) | 32 ± 4.8 | 32 ± 3.9 | / |
| LVEF (%) | 54 ± 7 | 54 ± 7 | / |
| LAD (mm) | 43 ± 6 | 43 ± 2 | / |
| Septum (mm) | 14 ± 2.2 | 13.5 ± 2 | / |
| Posteriorwall (mm) | 11 ± 1 | 10.5 ± 1 | / |
| MPI | 0.57 ± 0.03 | 0.49 ± 0.02 | / |
| LV mass (g) | 191.7 ± 49.7 | 178.3 ± 41.1 | / |
| LV mass/BSA (g/m2) | 82.62 ± 21.42 | 76.85 ± 17.72 | / |
| LV mass/h (m2) | 67.03 ± 17.38 | 62.34 ± 14.37 | / |
Clinical characteristics of obese patients with pre-diabetic condition (group 2) at baseline vs. 12 months of follow-up. In this table are reported the study variables of groups 2, 20 obese patients with pre-diabetic condition treated by a hypocaloric diet added to the placebo. In the study variables (first column to the left) are reported clinical variables, biohumoral markers, and echocardiographic parameters for each group of patients. We reported fasting glucose and lipid values. CRP, C reactive protein; g, grams; m, meters; h, height; HOMA_IR, homeostasis model for the assessment of insulin resistance; IL6, interleukine 6; LAD, left atrium diameter; LV, left ventricle; LVEF, left ventricle ejection fraction; LVTDd, left ventricle telediastolic diameter; LVTDs, left ventricle telesystolic diameter; MPI, myocardium performance index; TNFα, tumor necrosis factor alpha; WHR, waist hip ratio. The symbol
is indicating the p <0.05 by the comparison of group 2 at baseline vs. group 2 at 12 months follow-up.